Six-year results of first-line lenalidomide-rituximab versus rituximab-chemotherapy for advanced follicular lymphoma

The multinational phase 3 RELEVANCE trial randomised patients with previously untreated advanced follicular lymphoma (aFL) to lenalidomide plus rituximab (R²) or rituximab plus chemotherapy (R-chemo), followed by rituximab maintenance. The second interim analysis of the trial, after 6 years of follow-up, found no differences between the arms for the end points progression-free and overall survival. There were no new safety signals. The authors conclude that R² followed by rituximab maintenance continues to demonstrate comparable and durable efficacy and safety, and represents an acceptable chemotherapy-free regimen for previously untreated aFL.